Case Studies - Page 4

Partnering Strategy

Case Study Jun 11, 2022

Corporate and Pipeline Strategy and Development Roadmap

Case Study May 14, 2022

Strategic Development of Gene-Editing Platform Technology in Rare Disease Space

Case Study May 12, 2022

Corporate Strategy

Case Study May 11, 2022

Opportunity Assessment and Prioritization

Case Study Apr 12, 2022

Top Multinational Pharma Interested in Assessing/Onboarding ACT and/or Other IO Modalities; IO Landscape, Portfolio Gap Analysis, and BD Strategy Assessment

Case Study Apr 11, 2022

Multivariate Prioritization of Putative Targets, Indications and Specific Therapeutic Modalities

Case Study Mar 25, 2022

Public Preclinical Biotech with Differentiated ACT Platform in Need of Strategic Focus; Assessment/Prioritization of Putative Targets, Indications, and Enabling Tech

Case Study Mar 11, 2022

Platform Assessment, Indication Prioritization and Target Product Profile Development to Inform Development Plan and Competitive Differentiation

Case Study Mar 2, 2022

Portfolio Strategy and Opportunity Assessment to Support BD Decisions and Clinical Development

Case Study Feb 25, 2022

Modeling To Inform Payer Communications and Policy – Optimizing Treatment Sequences in Multiple Immunology Indications

Health systems view low-cost therapeutic alternatives (biosimilars and generics) as opportunities to reduce their medicine spend. However, this approach focuses on costs only and not outcomes, which results in the adoption of ‘low-cost first’ blanket policies regardless of biologic class or therapy area. Consequently, patients are left to cycle through low-cost options before they can access the most effective treatments

Case Study Feb 18, 2022